Anti-Mouse CD54 (Clone YN1/1.7.4) – Purified in vivo PLATINUM™ Functional Grade

Anti-Mouse CD54 (Clone YN1/1.7.4) – Purified in vivo PLATINUM™ Functional Grade

Product No.: C6391

[product_table name="All Top" skus="C2391"]

- -
- -
Clone
YN1/1.7.4
Target
CD54
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Ly-47, ICAM-1
Isotype
Rat IgG2b κ
Applications
CyTOF®
,
FA
,
FC
,
IHC FF
,
in vivo
,
IP
,
PhenoCycler®
,
WB

- -
- -
Select Product Size

Data

- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Mouse NS-1 cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this YN1/1.7.4 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this YN1/1.7.4 antibody for use in western blotting is 1-10 μg/ml.
Additional Applications Reported In Literature ?
PhenoCycler-Fusion (CODEX)®
CyTOF®
IP
Additional Reported Applications For Relevant Conjugates ?
B
IHC (Frozen)
For specific conjugates of this clone, review literature for suggested application details.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone YN1/1.7.4 recognizes an epitope on mouse CD54.
Background
ICAM-1 is a 55 kDa glycoprotein that is part of the Ig superfamily. It is heavily glycosylated to form 75 kDa to 115 kDa. ICAM-1 is known to be an adhesion and viral entry molecule, and its long suspected involevement in signal transduction is being elucidated. The signal-transducing functions of ICAM-1 appear to be mainly associated with proinflammatory pathways. Furthermore, ICAM-1 signaling appears to act as a beacon for inflammatory immune cells such as macrophages and granulocytes bringing about inflammation via lymphocyte trafficking. ICAM-1 is essential for the transmigration of leukocytes out of blood vessels and into tissues, and is a marker of endothelial dysfunction leading to damaging vascular disorders in umbilical and placental vascular tissue of gestational pregnancies. ICAM-1 is the receptor for rhinoviruses (the cause of most common colds) and malaria, and plays an inflammatory role in ocular allergies.
Antigen Distribution
CD54 is present on endothelial cells, lymphocytes, epithelial cells, dendritic cells and keratinocytes.
Ligand/Receptor
CD11a/CD18 (LFA-1) or CD11b/CD18 (Mac-1) and CD11c/CD18, CD43, hyaluronan, fibrinogen
Function
Immune reaction, inflammation, adhesion
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Costimulatory Molecules
.
Immunology
.
Innate Immunity
.
Neuroscience
.
Neuroscience Cell Markers
.
Stem Cell

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone YN1/1.7.4 is a monoclonal antibody targeting mouse CD54 (ICAM-1), most commonly used in vivo in mice to block CD54 function and study cell adhesion, leukocyte migration, and inflammatory processes.

Common in vivo applications of clone YN1/1.7.4 in mice include:

  • Functional blockade of CD54 (ICAM-1): Used to inhibit the interaction between CD54 and its ligands (LFA-1 and Mac-1), which is critical for leukocyte adhesion and transmigration during immune responses and inflammation.
  • Modulation of immune cell infiltration: Administration of YN1/1.7.4 in mouse models decreases neutrophil infiltration into inflammatory lesions and inhibits the production of pro-inflammatory cytokines such as CXCL1, IFNγ, and IL-17.
  • Investigation of cell-cell adhesion mechanisms: Blocking CD54 with YN1/1.7.4 allows researchers to dissect the role of ICAM-1 in antigen presentation and immune cell interactions, especially in the context of inflammation or autoimmunity.
  • Assessment of disease mechanisms: YN1/1.7.4 is employed in models of inflammatory diseases (e.g., arthritis, autoimmune conditions) to understand how CD54 contributes to pathology by facilitating immune cell migration and tissue infiltration.
  • In vivo blocking/neutralization assays: The antibody is widely used in protocols requiring a specific blockade of CD54’s function to establish its role in leukocyte dynamics and tissue injury.

Additionally, YN1/1.7.4 is suitable for immunohistochemistry and flow cytometry analysis of mouse tissues, but its functional blocking application is most relevant for in vivo studies of immune processes.

In summary, the principal in vivo applications of clone YN1/1.7.4 in mice are as a functional blocking tool for CD54 to study leukocyte adhesion, migration, and immune regulation in models of inflammation and immune-mediated disease.

Frequently, YN1/1.7.4, a monoclonal antibody targeting mouse CD54 (ICAM-1), is used in conjunction with antibodies against common immune cell surface markers, such as CD3, CD4, CD8, CD19, CD11b, CD11c.

In typical research applications like flow cytometry and immunohistochemistry, investigators combine YN1/1.7.4 with the following antibodies or proteins to delineate immune cell types and states:

  • CD3 (marker for T cells)
  • CD4 (marker for helper T cells)
  • CD8 (marker for cytotoxic T cells)
  • CD19 (marker for B cells)
  • CD11b (marker for monocytes/macrophages and some dendritic cells)
  • CD11c (marker for dendritic cells)

These combinations enable identification of CD54 expression across various immune cell subsets, measurement of activation/adhesion status, and investigation of cell-cell interactions during immune responses.

Additionally, in functional studies examining adhesion, YN1/1.7.4 is often used with antibodies or proteins targeting LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), which are key ligands for ICAM-1. These interactions are essential for T cell and leukocyte trafficking, so researchers may employ YN1/1.7.4 alongside:

  • Anti-CD11a
  • Anti-CD18
  • Anti-CD11b

Some publications also mention combining YN1/1.7.4 with other endothelial antibodies such as clone 390, especially in imaging perfused tissue segments to analyze vascular boundaries and antibody capture efficacy.

Isotype controls and secondary antibodies are standard for specificity and detection, with rat IgG2b often matched for controls in studies employing YN1/1.7.4.

In summary, the most commonly paired antibodies/proteins with YN1/1.7.4 in the literature are:

  • CD3, CD4, CD8, CD19, CD11b, CD11c (immune cell markers)
  • CD11a, CD18, CD11b (adhesion molecules, LFA-1, Mac-1 ligands/partners)
  • Clone 390 (another endothelial marker, in certain tissue imaging protocols)
  • Isotype controls, typically Rat IgG2b

Pairing YN1/1.7.4 with these antibodies allows researchers to investigate immune cell phenotypes, cell adhesion, and tissue localization in complex immunological settings.

Clone YN1/1.7.4 is a rat monoclonal antibody extensively used in scientific research for specific targeting and functional blockade of mouse CD54 (ICAM-1), and its main citations reveal several consistent key findings:

  • Functional Blockade: It effectively blocks the interaction between CD54/ICAM-1 and its integrin ligands, especially LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), resulting in inhibition of cell-cell adhesion and immune cell recruitment.
  • Suppression of Inflammatory and Immune Responses: In vivo studies using clone YN1/1.7.4 demonstrate its capacity to modulate inflammatory responses, block leukocyte endothelial transmigration, and thereby serve as a tool to study immune cell migration and CD54-dependent pathological processes such as inflammatory diseases and cancer.
  • Imaging and Binding: The antibody is highly effective for imaging applications (including flow cytometry and immunohistochemistry) because it rapidly and specifically binds endothelial, monocyte, lymphocyte, and dendritic cell–expressing CD54/ICAM-1. Fluorescence imaging using AF488-labeled YN1/1.7.4 allows visualization of immune cell interactions and tissue-level adhesion molecule distribution.
  • Antigen Presentation Modulation: By blocking ICAM-1, YN1/1.7.4 can alter antigen presentation processes in mouse models, influencing T cell activation and function.
  • Technical Quality for In Vivo Use: Studies cite its ultra-low endotoxin content and high purity, which are essential for sensitive animal experiments, minimizing nonspecific immune activation while enabling precise evaluation of antibody-mediated effects.
  • Epitope Specificity: Clone YN1/1.7.4 recognizes an epitope on mouse ICAM-1 distinct from other commonly used antibodies (e.g., eBioKAT-1), providing experimental flexibility and specificity for mechanistic studies.

These findings make YN1/1.7.4 a key tool for studying immune cell trafficking, inflammation, and barrier function across various mouse models used in immunology, oncology, and vascular biology.

Dosing regimens of clone YN1/1.7.4 (anti-mouse CD54/ICAM-1) vary depending on the mouse model, disease context, and experimental aim. There is no universal protocol, but published studies and supplier data provide typical regimens and methodologies.

Key variations in dosing regimens:

  • Dose amount:
    Doses can vary widely. For example, in studies involving in vivo immune modulation, 100 μg per mouse administered intraperitoneally three times per week for two weeks has been reported. For vascular navigation and antibody capture, studies have tested doses from 800 ng to 1200 ng per perfused segment in ex vivo liver models.

  • Dosing schedule:
    Some protocols use frequent, repeated dosing over weeks (e.g., 3x per week for 2 weeks). Shorter, single doses or acute perfusions are used in imaging or antibody capture studies.

  • Administration method:
    The clone has been administered intraperitoneally (IP) for systemic immune modulation, as well as locally by perfusion for vascular or imaging studies in organ segments. The route is selected based on experimental needs (systemic immunology vs. local vascular manipulation).

  • Mouse model and disease context:
    Variation is observed depending on the mouse strain (e.g., inbred, nude, immune competent) and disease context (e.g., cancer metastasis, inflammation, vascular studies).
    For example, colorectal cancer (CRC) liver metastasis models used doses designed to modulate liver vascular/immune responses.

  • Optimization:
    Titration is recommended for all applications. Each investigator is advised to determine optimal dilution and schedule for their specific setting and model.

Example regimens from the literature:

Application ContextDose & RouteFrequencyModel Details
Systemic immune modulation100 μg/mouse, intraperitoneally3×/week for 2 weeksC57BL/6 mice
Vascular imaging, ex vivo liver perfusion800–1200 ng per segment, local perfusionSingle applicationPerfused mouse liver segments
Flow cytometry (staining)≤ 0.25 μg per 10⁶ cells (in 100 μL)Single experimentFor cell analysis
Western blot1–10 μg/mLSingle experimentFor protein analysis

Conclusions and best practice:

  • Dosing regimens for clone YN1/1.7.4 must be tailored for each specific mouse model and research objective.
  • Published studies recommend careful titration, route selection, and pilot experiments to identify effective and non-toxic doses for each new application.

If you need a protocol for a specific disease model or mouse strain, please clarify for more tailored dosing recommendations.

References & Citations

1. Li, S. et al. (2009) Biochem. Biophys. Res. Commun. 381: 459 2. Wolf, S. et al. (2009) Pharmacol. Rep. 61: 22 3. Ozcan, U. et al. (2009) Arch Gynecol. Obstet.
CyTOF®
FA
Flow Cytometry
IHC FF
in vivo Protocol
Immunoprecipitation Protocol
PhenoCycler®
General Western Blot Protocol

Certificate of Analysis

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.